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Influenza impressively reflects the paradigm of a viral disease in which continued evolution of the virus 
is of paramount importance for annual epidemics and occasional pandemics in humans. Because of 
the continuous threat of novel influenza outbreaks, it is essential to gather further knowledge about 
viral pathogenicity determinants. Here, we explored the adaptive potential of the influenza A virus 
subtype H1N1 variant isolate A/Hamburg/04/09 (HH/04) by sequential passaging in mice lungs. Three 
passages in mice lungs were sufficient to dramatically enhance pathogenicity of HH/04. Sequence 
analysis identified 4 nonsynonymous mutations in the third passage virus. Using reverse genetics, 3 
synergistically acting mutations were defined as pathogenicity determinants, comprising 2 mutations in 
the hemagglutinin (HA[D222G] and HA[K163E]), whereby the HA(D222G) mutation was shown to 
determine receptor binding specificity and the polymerase acidic (PA) protein F35L mutation 
increasing polymerase activity. In conclusion, synergistic action of all 3 mutations results in a mice 
lethal pandemic H1N1 virus. 
 
 
The first pandemic of the 21st century arose in 2009 with the outbreak of the pandemic influenza A 
virus (IAV) subtype H1N1 variant (H1N1v) virus. Although the majority of infected people experienced 
mild symptoms, there were numerous reports of severe cases. It is thus mandatory to improve our 
understanding of factors that could contribute to the emergence of more virulent pandemic H1N1v 
strains in the future.  
Several studies that investigated the pathogenicity of different 2009 H1N1v isolates in ferrets, mice, 
and nonhuman primates revealed more effective virus propagation than did seasonal H1N1 strains [1–
3]. However, there are also reports showing that the 2009 H1N1v strains are not highly pathogenic for 
mice [4–6]. Belser and colleagues [4] demonstrated that H1N1v viruses exhibit mild to moderate 
virulence in mice compared with pathogenic strains like the 1918 H1N1 influenza virus. Sequence 
analysis of the 2009 pandemic virus isolates unraveled the lack of known determinants of high 
pathogenicity, such as a polybasic cleavage site in the hemagglutinin (HA) or a lysine at position 627 
of the polymerase basic 2 (PB2) protein (reviewed in [7, 8]). Even an introduction of some of these 
pathogenicity determinants, such as E627K and D701N in the PB2 protein, change of the premature 
stop codon in the polymerase basic 1 (PB1)–F2 protein, introduction of a K217E substitution in the 
  
nonstructural 1 (NS1) protein, or an 11–amino acid C-terminal truncation of the NS1 protein, had, if 
any, only minimal impact on virulence [5, 9–11]. 
On the basis of these results, we wanted to know whether the pathogenicity of a 2009 H1N1v isolate 
could be enhanced during passaging of the virus in a mammalian host system. The assumption that 
lung-to-lung passaging would increase pathogenicity was driven by findings of several previous 
reports [12–14]. Numerous studies have identified mutations within the HA [15–18] and the 
polymerase subunits as mediators of increased pathogenicity upon passaging in mice [6, 16, 18–20]. 
Here we provide evidence that 3 lung-to-lung passages of the IAV strain A/Hamburg/04/09 (HH/04) in 
mice were sufficient to strongly increase viral pathogenicity due to 4 nonsynonymous adaptive 
mutations, located within the gene segments coding for the polymerase acidic (PA) subunit (F35L) of 
the polymerase complex, the HA(K163E and D222G), and the neuraminidase (NA)(T32I). Using 
reverse genetics, we demonstrated that a single amino acid change within the PA(F35L) enhanced 
virulence in mice and concomitantly increased the viral polymerase activity. The sole introduction of 
the D222G point mutation within the HA was sufficient to increase pathogenicity in mice as well, 
although additional introduction of the HA(K163E) mutation further increased virulence. 
Taken together, our data demonstrate that only 3 passages in mice were sufficient to alter a low-
pathogenic H1N1v virus to a highly mouse-pathogenic variant with higher replication capability, which 
was due to the acquisition of only 3 synergistically acting point mutations. These data clearly confirm 
the potential risk for the emergence of highly pathogenic human H1N1v strains. 
 
 
Materials and Methods 
Cells, Viruses, and Infection Conditions 
A/Hamburg/04/2009 virus was obtained from the German National Reference Centre for Influenza 
(Brunhilde Schweiger, RKI). The virus was isolated from clinical specimens, and virus strains were 
passaged on Madin-Darby canine kidney (MDCK) cells. The infection procedure was performed as 
described elsewhere [21]. The mouse-adapted A/Hamburg/04/2009 (HH/04-3rd) was obtained upon 
passaging 3 times in mice lungs. MDCK cells were cultured in minimal essential medium (MEM; PAA 
Laboratories), whereas the human lung epithelial cell line A549 was cultivated in Dulbecco’s modified 
Eagle’s medium (DMEM; PAA Laboratories). The porcine kidney epithelial (PK-15) cell line was 
cultured in MEM with 0.1 mmol/L nonessential amino acids (Sigma-Aldrich) and 1.0 mmol/L sodium 
pyruvate (PAA Laboratories), and the chicken embryonic fibroblast (DF-1) cells were cultured in 
DMEM with 0.1 mmol/L nonessential amino acids and 1.0 mmol/L sodium pyruvate. Cell-culture media 
were supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen) and 100 U/mL penicillin 
(PAA Laboratories), and 0.1 mg/mL streptomycin (PAA Laboratories). 
 
Generation of Recombinant Influenza Viruses 
A set of 8 plasmids based on the bidirectional pHW2000 plasmid [22] was prepared for the influenza 
A/Hamburg/04/2009 virus by standard methods, allowing the rescue of recombinant wild-type (wt) and 
mutant viruses. Mutations in the gene segments were introduced by site-directed mutagenesis using 
the primers HA(K163E)(fwd:5′-caaagctcagcgaatcctacattaatg-3′), HA(K163E)(rev:5′-
cattaatgtaggattcgctgagctttg-3′), HA(D222G)(fwd:5′-acccaaagtgaggggtcaagaagggagaa-3′), 
HA(D222G)(rev:5′-ttctcccttcttgacccctcactttgggt-3′), PA(F35L)(fwd:5′-aatggaacaacaagtgcctg-3′), and 
PA(F35L)(rev:5′-tgtgcatattgcagccaacttgttagtttcg-3′), NA(T32I)(fwd:5′-gaaacataatctcaatatggattagccactc-
3′), NA(T32I)(rev:5′-gagtggctaatccatatagagattatgtttc-3′). Mutations in the PA gene segment of the 
SC35M virus were introduced by using the primers PA(F35L)(fwd:5′-gagacaaataaattggctgcaatatgcac-
3′) and PA(F35L)(rev:5′-gtgcatattgcagccaatttatttgtctc-3′). The generation of the recombinant viruses 
was carried out as described elsewhere [21], and the presence and propriety of the desired mutations 
were confirmed by sequencing. 
 
  
Whole Genome Sequence Analysis 
Total RNA was isolated from MDCK cells (6 hours; multiplicity of infection, 5) by using an RNeasy-
Mini-Kit (Qiagen) according to the manufacturer’s protocol. Transcription of the complementary DNA 
(cDNA) was performed using RevertAid H-Minus First Strand cDNA Synthesis Kit (Fermentas) and 
primers specific for all influenza virus gene segments (5′-agcaaaagcagg-3′) according to the 
manufacturer’s protocol. Whole genome sequencing was performed by the Institute of Hygiene, 
University hospital Muenster, Germany. 
 
Plaque Titration 
Supernatants of infected cells were collected at the time points indicated postinfection and used to 
assess the number of infectious particles (plaque titers) in the samples. Briefly, MDCK cells grown to 
90% confluence in 6-well dishes were washed with phosphate-buffered saline (PBS; PAA 
Laboratories) and infected with serial dilutions of the collected supernatants in PBS/bovine albumin for 
30 minutes at 37°C. The inoculum was aspirated, and cells were supplemented with 2 mL MEM/BA 
(medium containing 0.2% bovine serum albumin [Roth], 1 mmol/L MgCl2 [Roth], 0.9 mmol/L CaCl2 
[Roth] and 100 U/mL penicillin, and 0.1 mg/mL streptomycin) containing 0.6% Agar (Oxoid), 0.3% 
DEAE-Dextran (Pharmacia Biotech), and 1.5% NaHCO3 (Invitrogen); and incubated at 37°C, 5% CO2, 
for 2–3 days. 
 
Western Blot Assays 
For Western blot analysis, cells were lysed in radioimmunoprecipitation assay buffer (25 mmol/L Tris-
HCl [pH 8; Roth], 137 mmol/L NaCl [Roth], 10% glycerol [Roth], 0.1% sodium dodecylsulfate [Roth], 
0.5% sodium deoxycholate [Roth], 1% octylphenoxypolyethoxyethanol [IGEPAL; Sigma-Aldrich], 
2 mmol/L ethylenediaminetetraacetic acid [pH 8; Roth], 50 mmol/L sodium glycerophosphate [Roth], 
20 mmol/L sodium pyrophosphate [Roth], 1 mmol/L sodium vanadate [Sigma-Aldrich], 5 μg/mL 
leupeptin [Roth], and 5 mmol/L benzamidine [Sigma-Aldrich]) at 4°C. Supernatants were cleared by 
centrifugation, and protein content was determined by the Bradford method. Protein expression was 
analyzed by sodium dodecyl sulphate polyacrylamide gel electrophoresis and Western blot. Antiserum 
samples against the influenza virus protein M1 and against the cellular extracellular signal-regulated 
kinase 2 were obtained from Santa Cruz Biotechnology. 
 
Minireplicon Luciferase Assay 
Luciferase-reporter gene assays were carried out as described elsewhere [21]. A549 cells were 
transfected with a plasmid encoding an antisense luciferase-reporter gene flanked by the influenza 
virus promoters. The RNA produced by this plasmid represents a viral RNA template and is expressed 
by an RNA-Pol I promoter. This plasmid was transfected in addition to Pol II–driven constructs 
expressing the viral polymerase genes PB1, PB2, NP of the recombinant (rec) HH/04 virus strain, and 
PA of either the HH/04 virus strain or the rec HH/04-PA(F35L) mutant virus strain and the 
corresponding SC35M constructs, respectively. As a negative control, cells were transfected without 




All animal studies were performed in compliance with animal welfare regulations (permission number 
Az 8,87–50.10.36.09.007 by the State Agency for Nature, Environment and Consumer Protection 
[LANUV], Germany). Eight-week-old BALB/c mice were obtained from the animal-breeding facilities 
Harlan-Winkelmann. For infection of mice, the animals were anesthetized by intraperitoneal injection 
of 200 μL solution of ketamine (Ceva) and xylazin (Ceva; equal amounts of 2% xylazin solution and 
10% ketamine solution were mixed 1:10 with PBS). Mice were infected by the intranasal route with the 
  
indicated virus and plaque-forming units (PFU) in a 50 μL volume. In our experiments, due to 
protection of animal welfare restrictions, mice were killed upon a body weight loss of 25%.  
For determination of lung virus titer, mice were killed at the times indicated, and lungs were collected 
in PBS. The samples were homogenized using a FastPrep-24 homogenizator (MP Biomedicals) with 
Lysing Matrix D (MP Biomedicals), and were adjusted with PBS to obtain a 10% tissue homogenate. 
The samples were centrifuged at 10 000 rpm for 5 minutes, and the supernatants were taken.  
 
Structure Modeling 
Images of PA proteins were created with PyMOL Molecular Graphics System, Version 1.1 
(Schrödinger, LLC) with the help of the SWISS-MODEL Server [23] and the Protein Data Bank 




Adaptation of the Human H1N1v Isolate HH/04 to Mice 
To investigate the potential of HH/04 to adapt to a new mammalian host, the natural human isolate 
was passaged 3 times in mice, whereby the emerged virus was completely sequenced. Mice infected 
with a high dose of 10
6
 PFU did not show any symptoms of disease, consistent with a marginal body 
weight loss of <10% during the observation period (Figure 1A, filled circles). After the first passage, 
only a single mutation in the HA(K163E) was detectable. The isolated HH/04-1st virus was used for 
infection in a next passage (Figure 1A, open circles). Monitoring of the body weight loss revealed no 
differences in comparison to HH/04, illustrating that the single HA mutation (K163E) alone has no 
impact on virulence. Sequencing of the second passage isolate (HH/04-2nd) revealed 3 additional 
nonsynonymous mutations within the HA, PA, and NA, and 1 synonymous mutation within the NA 
gene segment (Figure 1B). These 3 additional mutations indeed led to enhanced pathogenicity, as 
evidenced by a pronounced body weight loss of HH/04-2nd–infected mice (Figure 1A, open squares). 
Subsequent sequencing of the third passage isolate (HH/04-3rd) revealed that the previously emerged 
mutations were stable without any appearance of further mutations. 
 
Increased Pathogenicity of the Mouse-Adapted HH/04-3rd Isolate 
In contrast to the HH/04 virus, infection of mice with the HH/04-3rd–passage isolate resulted in 
increased body weight loss (Figure 2A) and enhanced lung virus titers (Figure 2B), which was 
accompanied by 80% lethality (Figure 2C). Our results clearly indicate that the almost apathogenic 
human HH/04 isolate can be adapted to a new mammalian host after only 2–3 lung-to-lung passages. 
 
Mutations Within the Hemagglutinin and the PA Subunit of the Polymerase Complex Are 
Responsible for Enhanced Mouse Pathogenicity 
We generated a recombinant 8 plasmid set for the recovery of recombinant HH/04 viruses. The 
identified nonsynonymous mutations were introduced separately or in combination into the genome of 
9 recombinant HH/04 viruses, designated as rec HH/04, rec HH/04-3rd, and HH/04-HA(K163E); 
HH/04-HA(D222G); HH/04-PA(F35L) and HH/04-NA(T32I). Furthermore, the HH/04-
HA(K163E+D222G) variant, containing both mutations in the HA, HH/04-HA(K163E+D222G) 
PA(F35L), and HH/04-HA(K163E+D222G) NA(T32I) mutants carrying the indicated changes were 
created. To show that the introduction of the 4 mutations in HH/04 reflects the phenotype of the 3rd-
passage HH/04, the weight loss (Figure 3A) and lung virus titers (Figure 3B) of mice infected with 
HH/04, rec HH/04, HH/04-3rd, and rec HH/04-3rd were determined. Both parameters were almost 
identical when HH/04 was compared with rec HH/04 and HH/04-3rd to rec HH/04-3rd, respectively. 
Thus, the recombinant virus and the genetically engineered variant exhibited a similar replication 
behavior and pathogenicity as their natural counterparts.  
  
To analyze the impact on virulence of each single adaptive mutation, mice were infected with rec 
HH/04 and 4 virus mutants, each containing the indicated single mutation (Figure 4A). By monitoring 
body weight loss, a strong contribution of the HA(D222G) and PA(F35L) mutations to increased 
virulence was detected. In contrast, the HA(K163E) and NA(T32I) mutations alone did not affect viral 
pathogenicity to a large extent. In contrast, examination of double- and triple-mutant viruses revealed 
a supplementary contribution of the HA(K163E), and just to a minor extent, of the NA(T32I) mutation to 
increased virulence (Figure 4B). In this low-dose infection experiment, the rec HH/04-
HA(K163E+D222G) PA(F35L) virus indeed showed higher additive effects of the PA(F35L) mutation 
compared with the NA(T32I) mutation for virulence, although the NA(T32I) impact on virus virulence 
cannot completely be neglected. 
 
PA(F35L)-Dependent Increase of Virulence Correlates With Enhanced Viral Polymerase Activity 
As part of the heterotrimeric RNA-dependent RNA polymerase, the PA contributes to diverse functions 
such as endonuclease and protease activities, cap-binding, and cap-snatching, as well as viral RNA 
binding [24–28]. A likely explanation for enhanced pathogenicity of the HH/04-PA(F35L) variant could 
be that the PA mutation confers enhanced polymerase activity. We studied the polymerase activity of 
the HH/04-PA(F35L) virus in comparison to the rec HH/04 strain in a minireplicon assay, allowing the 
relative quantification of viral polymerase activity. Reconstitution of the polymerase complex with a PA 
containing the F35L mutation resulted in a 2.5-fold higher polymerase activity compared with the PA-
wt protein (Figure 5A). This was not a strain-specific phenomenon because the same mutation in the 
background of the avian influenza virus A/Seal/Massachusetts/1/80 (H7N7) mouse-adapted strain 
(SC35M; Figure 5B) showed a similar result. To examine whether this enhanced polymerase activity 
improves the replication efficiency, different cell lines were infected with the rec HH/04 and rec HH/04-
PA(F35L). Viral protein accumulation and virus propagation were examined by determination of the 
viral M1-protein synthesis and progeny virus titers. Upon infection with HH/04-PA(F35L), an increase 
of both viral protein amounts (Figure 5C) and virus titers (Figure 5D) was detected. This phenomenon 
was not dependent on the cell type used because infection of different cell lines resulted in a similar 
increase in polymerase activity if the F35L mutation was present in the PA. Taken together, these 
results clearly indicate a replication advantage conferred by the F35L mutation in the PA, which is 
most likely the molecular basis for enhanced virulence in PA(F35L)-infected mice. 
 
Discussion 
Adaptation is a major driving force in evolution, whereby beneficial mutations within the genome 
become manifest and result in adaptation to a novel host, accompanied by increased fitness and 
enhanced propagation. Taking this into account, it is likely that pandemic H1N1 viruses may acquire 
enhanced virulence caused by adaptive mutations during propagation and spreading among humans 
and/or pigs.  
In the present study, the mouse-adapted virus strain showed increased pathogenicity illustrated by 
increased body weight loss and mortality, as well as increased replication capacity in mice lungs 
(Figure 2A–C). Four nonsynonymous mutations were identified via whole genome sequence analysis 
(Figure 1B). Among these, 3 mutations within the PA and the HA were recognized as a cause of the 
increased pathogenicity. The aspartic acid to glycine exchange D222G within the hemagglutinin of 
2009 H1N1v viruses could be epidemiologically correlated to severe cases of illness in several 
countries [29–31]. In 1 out of 6 H1N1v-infected patients with primary severe respiratory failure treated 
at the intensive care unit of the university hospital Muenster in 2009, we were able to demonstrate that 
the HA(D222G) mutation arose simultaneously with the oseltamivir resistance mutation H275Y in the 
NA (data not shown). In this 31-year-old previously healthy male patient, virus isolated on day 1 after 
admission and initiation of the oseltamivir treatment (influenza A/Nordrhein-Westfalen/172/09, RKI) still 
contained the wt sequence (HA D222, NA H275) and was phenotypically oseltamivir sensitive. In a 
subsequent isolate obtained on day 5 after admission and completion of the oseltamivir therapy 
(influenza A/Nordrhein-Westfalen/173/09) and in all following isolates, the respective mutations were 
present and isolates were phenotypically oseltamivir resistant. This case clearly highlights the existing 
risk of further adaptation, leading to high virulent and nondrug-treatable virus variants. A D222G 
change in the HA protein of pandemic 2009 IAV led to broader binding range of alpha 2,3-linked sialyl 
receptor sequences [32, 33].  
  
 
In mice, the D222G mutation is related to higher virus titers, elevated proinflammatory cytokine release 
in the lungs, and enhanced lethality [34]. Furthermore, similar H1N1v mice adaptation approaches 
detected the HA(D222G) mutation as well [35, 36], possibly indicating the necessity of an α 2,3-linked 
sialyl receptor binding specificity for efficient replication in mice [37]. It is conspicuous that mutations in 
the HA were most often accompanied by mutations within the polymerase complex, especially in the 
PA protein [35, 36, 38]. These data are in line with our results regarding the importance of the 
HA(D222G) mutation for the virulence of pandemic H1N1 viruses. Nevertheless, body weight loss of 
rec HH/04-HA(D222G)–infected mice was less severe as of rec HH/04-3rd–infected mice (Figure 4B), 
revealing the strong involvement of further mutations contributing to the increased virulence, which 
highlights synergistic effects of several mutations in combination.  
 
The increase of virulence due to the HA(D222G) mutation is further enhanced by introduction of the 
HA(K163E) mutation, as indicated by the increased body weight loss of HA(K163E+D222G) double 
mutant–infected mice (Figure 4B). Similar to the amino acid at position 222 in the HA, the amino acid 
at position 163 is described as an antigenic site in H1-HA. Whereas amino acid 222 is located in the 
Ca epitope, amino acid 163 is closely located to the receptor-binding site in the Sa epitope [39, 40]. 
Additional introduction of either the PA or the NA mutation to the double-mutant virus revealed a 
stronger contribution of PA mutation to increased virulence as against the NA mutation, as it was 
expected from the single-mutant infection studies (Figure 4A).  
During the virus life cycle, the PA protein is mainly responsible for transcription and replication of the 
viral RNA. The messenger RNA (mRNA) caps are snatched 10–14 nucleotides behind the 5′ cap from 
host pre-mRNAs by a distinctive, still not fully dissolved mechanism [41–44]. Recently, it was shown 
that the endonuclease activity of the polymerase complex is located in the N-terminal part of the PA 
subunit [24, 28]. These functions of the PA led us to the concept that enhanced body weight loss of 
mice could be due to more efficient virus propagation caused by increased polymerase activity. 
Indeed, the polymerase activity of PA(F35L) viruses outperformed 2 wild-type viruses of the H1 and 
H7 subtypes by 2- to 2.5-fold in a minireplicon assay (Figure 5A and 5B). Consistent with this finding, 
the increased polymerase activity also led to enhanced replication efficiency in cultured cells from 
different species.  
 
The concept of optimized interactions among viral proteins and host cell factors as being partially 
responsible for adaptation to a new host was reported to be a determinant of host range [45]. At 
present, we cannot exclude that the PA(F35L) mutation improves the activity of the viral polymerase 
by enhancing its association with host cell factors in mice. However, given the result that the PA(F35L) 
variation increases viral polymerase activity in both human and murine cells (Figure 5C and 5D), we 
favor the hypothesis that this variation rather functions in a host-independent manner, possibly by 
improving the catalytic activity of the viral enzyme. Although precise and entire functions of PA still 
remain unclear, the PA is known to contribute to several steps during the replication process. Thus, 
numerous functions can be affected by the F35L mutation improving polymerase activity. The N-
terminus of HH/04-PA displays amino acid 35 to be located in the α-helix 3, as shown in the 
computationally 3-dimensional (3D) structure prediction approach (Figure 6A and 6B).  
 
This amino acid is closely located to histidine 41, which is part of the endonuclease active site and 
seems to be responsible for binding of divalent cations [24, 28]. The structure prediction of the 
PA(L35) protein reveals an unaltered protein structure and also no apparent change in the orientation 
of the marked residues. Sequence alignment of 2 representative IAV (H3N2 and H5N1) strains [24] 
reveals conserved sequences from amino acid 29 throughout the whole α-helix 3 of both strains, 
comparable to HH/04. Leucine at position 35 matches to the consensus sequence of influenza B 
viruses that also contain an identical H41 active site residue. Apart from that, a sequence alignment of 
human IAV strains (National Center for Biotechnology Information Influenza Virus Resource Database) 
reveals 8 pandemic 2009 H1N1 strains, comprising the amino acid leucine at position 35 within the 
PA. In addition to the 8 pandemic 2009 H1N1 strains, the mutation also emerged in 2 strains isolated 
in the forties and in 2 high-virulent H5N1 human isolates. These data clearly highlight the possibility of 
natural occurrence of the PA(F35L) mutation in humans, emphasizing the potential risk of the 
emergence of highly virulent pandemic H1N1 viruses in humans. 
It would be interesting to know whether the emerged adaptive mutations originate de novo or were 
selected from preexisting quasispecies. Because the study was initiated with a natural isolate that was 
obtained by an oral cavity swap of an infected patient, the existence of quasispecies within the 
  
inoculum cannot be totally ruled out. A closer look on the sequencing chromatograms of the HA 
(position 163) and NA (position 32) in the origin strain possibly reveals mixed populations within the 
inoculum (Figure 1B). However, similar to the natural isolate, enhanced pathogenicity in mice also was 
observed after 3 passages of the genetically defined recombinant HH/04, where quasispecies do not 
play a role (data not shown). Thus, although selection of quasispecies may occur, there is also de 
novo selection of variants.  
In summary, this new HH/04-3rd variant is characterized by increased virulence primarily due to 
HA(K163E), HA(D222G), and the PA(F35L) mutations, which can be defined as pathogenicity 
determinants that are mainly responsible for enhanced virulence. Our data furthermore clearly 
illustrate that the examination of single-pathogenicity determinants for the assessment of enhanced 
viral pathogenicity can be somehow insufficient, highlighting the need to take the synergistic action of 
pathogenicity determinants for increased virulence into account. In these adaptation approaches, 2 
events seem to have occurred for adaptation of pandemic 2009 H1N1v strains to mice. On the one 
hand, an optimized HA-dependent receptor binding specificity (probably leading to changes in 
attachment to different cell types [32, 37]), and on the other hand, increased replication efficiency 
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Tables and Figures 
 
 
Figure 1. H1N1v adapted to a new mammalian host upon passaging in mice lungs. A, Three 8-week-old BALB/c 
mice were intranasally infected with 106 PFU of HH/04, HH/04-1st, and HH/04-2nd, and body weight (6 SD) was 
monitored. B, Sequences of HH/04 and HH/04-3rd were compared, and identified mutations are depicted. 
Abbreviations: H1N1v, influenza A virus subtype H1N1 variant; HH/04, H1N1 variant isolate A/Hamburg/04/09; 
PFU, plaque-forming units. 
  
Figure 2. Mouse-adapted HH/04-3rd showed increased virulence. A–C, Five 8-week-old BALB/c mice were 
intranasally infected with 106 PFU of HH/04 and the HH/04-3rd, respectively. A, Body weight (6 standard 
deviation) of the infected mice was monitored over a time period of 5 days. B, Virus titers of infected lungs were 
determined 3 days postinfection in standard plaque titrations (mean titers, HH/04: 3.4 3 105 PFU/mL to HH/04-3rd: 
1.6 3 106 PFU/ mL). Statistical significance was assessed by Student t test. *P , .05. C, Survival of the infected 
mice was monitored over a time period of 10 days. 
Abbreviations: HH/04, H1N1 variant isolate A/Hamburg/04/09; PFU, plaque-forming units. 
 
  
Figure 3. Comparison of recombinant (rec) and nonrecombinant virus strains. A, B, Four 8-week old BALB/c 
mice were infected intranasally with 5 3 104 PFU of HH/04, rec HH/04, HH/04-3rd and rec HH/04-3rd, 
respectively. A, Body weight of the infected mice was monitored over a time period of 6 days.  
B, Virus titers of infected lungs were determined 6 days postinfection in standard plaque titrations. Statistical 
significance was assessed by Student t test. *P , .05. Abbreviations: PFU, plaque-forming units; HH/04, H1N1 
variant isolate A/Hamburg/04/09. 
 
  
Figure 4. Impact of obtained mutations for enhanced virulence. Four 8-week-old BALB/c mice were infected 
intranasally with 2 3 105 PFU (A ) and 1 3 102 PFU (B ) of the indicated viruses and were monitored for body 




Figure 5. Increased replication ability of PA(F35L) mutant virus strain due to increased polymerase activity. A, B, 
Human lung epithelial cell line (A549) cells were transfected with a plasmid encoding an antisense luciferase-
reporter gene flanked by influenza virus promoters.  
The RNA produced by this plasmid represents a viral RNA template and is expressed via RNA-Pol I promoter. 
This plasmid was transfected in addition to Pol II–driven constructs expressing the viral polymerase genes PB1, 
PB2, and NP of (A ) the recombinant (rec) HH/04 strain and PA of either the rec HH/04 strain or the rec HH/04-
PA(F35L) mutant strain.  
In (B ), instead of the influenza rec HH/04 virus constructs, the corresponding constructs of the influenza 
A/Seal/Massachusetts/1/80 (H7N7) mouse-adapted virus strain were applied. As negative control, cells were 
transfected without any PA expression construct. Cells were lysed 24 hours posttransfection, and luciferase 
activities were determined. The value obtained with the PA-wt plasmid set was arbitrarily set to 100%. C, D, A549 
cells, chicken embryonic fibroblast (DF-1) cells, porcine kidney epithelia cells (PK-15), and mouse pulmonary 
squamous cell carcinoma cells (ASB-XIV) were infected with a multiplicity of infection of 1 of either rec HH/04 or 
rec HH/04-PA(F35L). Eight hours postinfection, viral M1-protein accumulation was detected by Western blot 
analysis (C ), and virus titers were determined in standard plaque titrations (D ). A–D, Data show the 
representative result of at least 3 independent experiments. Statistical significance was assessed by Student t 
test. 
*P , .05. A, C, D, Error bars represent SD. Abbreviations: PA, polymerase acidic; PB1, polymerase basic 1; PB2, 




















Figure 6. Three-dimensional structure models of the PA-N-terminal part. Ribbon representation of PA-F35 (A) 
and PA-L35 (B ) N-terminal (1-196) protein structure model of HH/04 with a-helices in red, b-strands in yellow, 
and loops in green. A, B, The key active site residue (H41) and residues 35 are indicated in stick representation 
and are colored in black. Abbreviations: PA, polymerase acidic; HH/04, H1N1 variant isolate A/Hamburg/04/09. 
 
 
 
